Abstract

Nimble deployment of universal characterization methods early in clinical development can enable rapid process development and advance product understanding. In today's talk, we will highlight areas where we have implemented conventional and native MS based approaches to characterize heterogeneity and quantitatively assess average drug-load and drug-distribution on ADCs. Going forward, we see the growth of native MS based approaches that are robust, quantitative and applicable to a wide variety of ADC modalities as being one of the key enablers of fast-to-clinic development of therapeutic molecules that have the potential to help patients.